Pictet Asset Management Holding SA Sells 40,336 Shares of Krystal Biotech, Inc. $KRYS

Pictet Asset Management Holding SA decreased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 20.5% during the fourth quarter, Holdings Channel.com reports. The fund owned 156,568 shares of the company’s stock after selling 40,336 shares during the quarter. Pictet Asset Management Holding SA’s holdings in Krystal Biotech were worth $38,600,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in KRYS. Perigon Wealth Management LLC increased its stake in Krystal Biotech by 0.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,970 shares of the company’s stock worth $2,211,000 after acquiring an additional 41 shares during the last quarter. Sound View Wealth Advisors Group LLC boosted its position in shares of Krystal Biotech by 2.9% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 2,003 shares of the company’s stock valued at $354,000 after acquiring an additional 56 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its position in shares of Krystal Biotech by 1.2% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 5,086 shares of the company’s stock valued at $1,254,000 after acquiring an additional 61 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Krystal Biotech by 5.0% in the third quarter. Bellevue Group AG now owns 1,312 shares of the company’s stock valued at $232,000 after purchasing an additional 62 shares in the last quarter. Finally, Bessemer Group Inc. grew its holdings in shares of Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after purchasing an additional 77 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ:KRYS opened at $259.95 on Thursday. The firm has a market capitalization of $7.65 billion, a PE ratio of 37.95 and a beta of 0.54. The stock’s fifty day moving average is $261.73 and its 200 day moving average is $245.55. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Krystal Biotech had a net margin of 52.64% and a return on equity of 18.69%. The company had revenue of $107.11 million during the quarter, compared to analyst estimates of $105.30 million. Equities analysts forecast that Krystal Biotech, Inc. will post 7.58 EPS for the current year.

Insider Activity

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $267.60, for a total value of $200,700.00. Following the sale, the chief accounting officer directly owned 22,366 shares of the company’s stock, valued at $5,985,141.60. This represents a 3.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Daniel Janney sold 11,803 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $275.59, for a total transaction of $3,252,788.77. Following the completion of the sale, the director directly owned 73,293 shares of the company’s stock, valued at approximately $20,198,817.87. The trade was a 13.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 129,164 shares of company stock worth $34,538,578 over the last 90 days. Insiders own 13.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on KRYS shares. Weiss Ratings raised shares of Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, April 9th. Guggenheim lifted their price objective on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. TD Cowen restated a “buy” rating on shares of Krystal Biotech in a report on Friday, January 9th. Citigroup upped their target price on shares of Krystal Biotech from $336.00 to $371.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Finally, Bank of America increased their price target on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $326.25.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.